The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer
- 1 January 1992
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 21 (S4) , 91-95
- https://doi.org/10.1002/pros.2990210514
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843The Journal of Steroid Biochemistry and Molecular Biology, 1990
- Endocrine Management of Prostatic CancerPublished by Walter de Gruyter GmbH ,1988
- Antiandrogene in der Therapie des fortgeschrittenen ProstatakarzinomsPublished by Springer Nature ,1987
- Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male ratsThe Prostate, 1987
- Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological GroupJournal of Urology, 1986
- Effect of Flutamide or Cyproterone Acetate on Pituitary and Testicular Hormones in Normal MenJournal of Clinical Endocrinology & Metabolism, 1984
- Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial*British Journal of Urology, 1980
- Cyproterone Acetate in the Treatment of Advanced Carcinoma of the ProstateJournal of Urology, 1973